Pfizer Inc (PFE)

PFE (NYSE:Drugs)
$32.77
pos +0.32
+0.99%
Today's Range: 32.17 - 32.85 | PFE Avg Daily Volume: 24,493,700
Last Update: 01/26/15 - 4:12 PM EST
Volume: 26,714,228
YTD Performance: 4.17%
Open: $32.44
Previous Close: $32.45
52 Week Range: $27.51 - $33.50
Oustanding Shares: 6,300,657,237
Market Cap: 206,724,563,946
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 7
Moderate Buy 1 1 1 1
Hold 3 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.92 2.00 2.00 2.00
Latest Dividend: 0.28
Latest Dividend Yield: 3.41%
Dividend Ex-Date: 02/04/15
Price Earnings Ratio: 20.25
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
20.25 19.90 26.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
13.46% 4.64% 49.47%
GROWTH 12 Mo 3 Yr CAGR
Revenue -12.50 -0.24 -0.09
Net Income 51.20 0.38 0.11
EPS 64.40 2.14 0.46
Earnings for PFE:
EBITDA 22.78B
Revenue 51.58B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.53 $0.51 $2.26 $2.19
Number of Analysts 8 3 11 12
High Estimate $0.56 $0.55 $2.29 $2.35
Low Estimate $0.52 $0.49 $2.24 $2.05
Prior Year $0.56 $0.57 $2.22 $2.26
Growth Rate (Year over Year) -4.69% -10.53% 1.72% -2.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

David Katz

 | Jan 6, 2015 | 9:00 AM EST

Try these stocks for dividend income instead.

By

Jim Cramer

 | Jan 5, 2015 | 10:00 AM EST

The next 10 Dow components in my analysis.

By

David Katz

 | Jan 2, 2015 | 9:00 AM EST

Every dog has its day.

By

Jim Cramer

 | Dec 15, 2014 | 3:24 PM EST

Reeling off the positives, even though the averages are in the red.

By

David Katz

 | Nov 25, 2014 | 2:30 PM EST

Whether it's acquiring or the acquired, Mylan is building shareholder value.

By

Kate Stalter

 | Nov 21, 2014 | 2:00 PM EST

Let's take a little tour through the various equity asset classes.

By

Sham Gad

 | Nov 12, 2014 | 3:00 PM EST

Bill Ackman is betting on Zoetis -- and you should, too.

By

Antonia Oprita

 | Nov 6, 2014 | 5:30 AM EST

U.K. authorities launch another probe into banks' conduct.

By

Gary Dvorchak

 | Oct 31, 2014 | 9:00 AM EDT

Some investment goodies to choose from.

By

Kate Stalter

 | Oct 30, 2014 | 2:00 PM EDT

Some growth leaders in the sector are getting technical support.

Shares of Colgate-Palmolive are under pressure again today. On Friday CL dropped ove...
In a perfect intermediate-term set-up, I would like to see the Market Vectors Gold Miners ...
I suspect with the events of the past couple weeks we won't see much push toward a shift i...
Homegoods retailer Bed, Bath & Beyond (BBBY) was hit hard a couple of weeks ago, dropp...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.